[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-prevention-of-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-prevention-of-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,84,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100637216","pharmacy-based-opportunistic-atrial-fibrillation-screening-integrated-with-emergency-services-numaplus-fa-100637216",false,"NCT07598903","Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)","Pharmacy-based Opportunistic Screening for Atrial Fibrillation Using a Portable ECG Device Integrated With Emergency Medical Services: a Prospective Type-1 Hybrid Implementation Study (NUMAPLUS Project)","Numaplus_FA","Inclusion Criteria:\n\n1. Age 65 years or older\n2. Attending a participating community pharmacy for any routine healthcare purpose\n3. No prior documented or patient-reported diagnosis of atrial fibrillation\n4. Capacity to provide written informed consent\n\nExclusion Criteria:\n\n1. Confirmed prior diagnosis of atrial fibrillation\n2. Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device\n3. Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope)\n4. Concurrent participation in another cardiac rhythm monitoring study\n5. Inability to maintain the required position for a 30-second ECG recording","ALL","65 Years",{"count":20,"type":21},380,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).",[27,28,29,30],"Atrial Fibrillation (Prevention of Stroke)","Arrythmia, Cardiac","Mass Screening","Pharmacies",[32,33,34,35,36,37,38,39],"atrial fibrillation","opportunistic screening","community pharmacy","RE-AIM","implementation science","emergency medical services","portable ECG","hybrid implementation study","NOT_YET_RECRUITING","2026-05-20",{"date":43,"type":44},"2026-05-22","ACTUAL",{"date":46,"type":21},"2026-06-01",{"date":48,"type":21},"2026-12-31",{"name":50,"class":51},"Centro de Emergencias Sanitarias 061 Andalucía","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100624296","the-southern-norway-post-stroke-atrial-fibrillation-study-100624296","NCT07407790","The Southern-Norway Post-Stroke Atrial Fibrillation Study","SNAPS","Inclusion Criteria:\n\n* Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.\n* Initial evaluation of CT and\u002For CT angiography and\u002For MRI supports a diagnosis of TIA or ischemic stroke.\n* Available smartphone and access to the ECG247-app to be able to participate in the study.\n* Estimated life span of \\>6 month\n* Permanent address in Norway\n* Informed Consent, Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n* Known AF or atrial flutter prior to inclusion\n* Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).\n* Implanted pacemaker, ICD or loop-recorder\n* \\>70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound\n* Pregnancy","18 Years",{"count":62,"type":21},450,[24],"This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.\n\nThe study will include approximately 450 adults who have had a stroke or a transient \"mini-stroke\" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:\n\n* Group 1 (Intervention): Participants wear the \"ECG247 Smart Heart Sensor.\" This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.\n* Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a \"Holter monitor\" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.\n\nThe main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.",[66,27,67,68,69],"Atrial Fibrillation (AF)","Ischemic Stroke","Secondary Prevention","Arrhythmia Atrial",[71,32,72],"stroke","anticoagulation","RECRUITING","2026-02-05",{"date":76,"type":44},"2026-02-12",{"date":78,"type":44},"2026-01-10",{"date":80,"type":21},"2029-12",{"name":82,"class":83},"Sorlandet Hospital HF","OTHER_GOV",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":52},"100589046","stroke-risk-assessment-and-markers-of-blood-clotting-in-patients-with-newly-diagnosed-non-valvular-atrial-fibrillation-nvaf-who-have-not-received-oral-anticoagulation-therapy-oac-therapy-prior-to-inclusion-100589046","NCT06949319","Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion","Individualized Stroke Risk Scores and Hemostatic Profile in Oral Anticoagulant-naïve (OAC-naïve) Patients With Non-valvular Atrial Fibrillation (NVAF)","BIO-AF","Inclusion Criteria:\n\n* Patients with newly diagnosed non-valvular atrial fibrillation (NVAF), who are oral anticoagulant-naïve (OAC-naïve) prior to inclusion.\n* Age ≥ 18 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Ongoing OAC treatment prior to inclusion.\n* Valvular AF (mechanical heart valves or moderate-severe mitral stenosis).\n* Secondary AF due to an acute reversible precipitant (e.g., infection, surgery, thyrotoxicosis, etc.).\n* Pregnant or breastfeeding women.\n* Treatment with oral contraceptives.\n* End-stage renal disease (creatinine clearance \\\u003C15 mL\u002Fmin as calculated by the Cockcroft-Gault equation).\n* Connective tissue diseases.\n* Active cancer (cancer diagnosis not followed by curative procedures six months from the date of diagnosis).\n* Major surgery (\\\u003C three months).\n* Acute coronary syndrome, stroke\u002FTIA, and venous thromboembolism within three months prior to inclusion.\n* Thrombophilia.\n* Significant liver disease.\n* Significant hematological disease.",{"count":93,"type":21},150,"OBSERVATIONAL","Background:\n\nAtrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF. AF increases the risk of death, heart failure, and stroke, which severely affect patients and also lead to high healthcare costs. Around 25% of all strokes are caused by AF, and patients with stroke due to AF tend to have a higher risk of death and more disability compared to stroke patients without AF.\n\nStroke prevention is, therefore, an important part of AF treatment, in which blood thinning medication has an important role. However, blood thinners increase the risk of bleeding. Therefore, it is important to divide patients with AF into different risk groups, known as risk assessment, to figure out who will benefit the most from blood thinners. To be able to divide patients into different risk groups, various stroke risk assessment tools have been developed, such as the CHA2DS2-VASc score and the ABC-stroke score. The most commonly used tool is the CHA2DS2-VASc score, including only clinical risk factors, such as high blood pressure, diabetes, etc. The ABC-stroke score, which includes blood markers of heart function, has been proven to outperform the CHA2DS2-VASc score in terms of predicting stroke in AF patients. However, the CHA2DS2-VASc score remains the primary stroke risk assessment tool for AF patients in current guidelines.\n\nAfter looking at the different risk factors, patients are divided into three groups: low, intermediate, and high risk. High-risk patients must take blood-thinning medication for life, while low-risk patients do not need it. In the medium-risk group, it remains uncertain whether blood thinners should be given or not.\n\nDespite the broad use of the CHA2DS2-VASc score, the score itself has limitations. The score does not include important factors, such as the duration of AF, the size and function of the upper heart chambers, as well as the stiffness of the heart, and markers of blood clotting, which are proven markers of a state that inceases the risk of blood clots. Furthermore, the CHA2DS2-VASc score does not consider whether heart failure, high blood pressure, and diabetes are well-controlled or not, which could lead to overuse of blood thinners. Therefore, the current risk assessment tools for patients with AF are incomplete, and improvements are needed.\n\nOverall hypothesis:\n\nOverall hypothesis is that the different components of the CHA2DS2-VASc score and ABC-stroke score affect blood clotting markers differently, depending on whether conditions like heart failure, high blood pressure, and diabetes (modifiable risk factors) are well-controlled or not. Investigators also expect to see differences in blood clotting markers across different stroke risk groups (low, intermediate, and high risk, based on the CHA2DS2-VASc score and ABC-stroke score) in AF patients who have not yet started blood thinning medication. Furthermore, investigators believe that the duration of AF, the size\u002Ffunction of the upper heart chambers, as well as the stiffness of the heart, can reflect an increased risk of blood clots in AF patients.\n\nOverall goal of the study:\n\nThe overall goal of the study is to help improve the current tools used to assess the risk of stroke in patients with newly diagnosed AF. This will be done by adding more factors to the current risk assessment tools that reflect an increased risk of stroke, such as the burden of AF, the size\u002Ffunction of the heart's upper chambers, as well as the stiffness of the heart, and using biomarkers that show the blood's ability to clot as a substitute measure for stroke risk.\n\nMethods:\n\nThe study is a cross-sectional, single-center observational study and will take place at Esbjerg Hospital - University Hospital of Southern Denmark, involving collaboration between the Unit for Thrombosis Research, Department of Clinical Diagnostics and the Department of Cardiology.\n\nThe study population will consist of 150 participants with newly diagnosed AF. The participants must not be taking a specific type of blood thinner, called anticoagulant therapy (OAC-therapy), before being included in the study. The participants will be recruited with the help of the general practitioners (GPs). The general practitioners will be thoroughly informed about the study and the importance of waiting to start OAC-therapy until the participants have been seen at the cardiology outpatient clinic. The participants will be scheduled for a blood test, an ultrasound of the heart (echocardiography), and a 7-day heart rhythm monitoring within 4 days after their first meeting with the GP.",[66,27,97,98,99,100,101],"Atrial Fibrillation New Onset","Non Valvular Atrial Fibrillation","Stroke (in Patients With Atrial Fibrillation)","Stroke","Thrombosis",[103,104,105,106,107,108,109,110,111,112,113,100,114,115],"Stroke risk assessment in patients with atrial fibrillation","OAC-naïve patients with newly diagnosed atrial fibrillation","Hemostatic biomarkers","CHA2DS2-VASc score","ABC-stroke score","AF-burden","Left Atrial Function Index (LAFI)","Echocardiography","HFA-PEFF score","H2FPEF score","Heart failure with preserved ejection fraction (HFpEF)","Oral anticoagulant therapy","Non-valvular atrial fibrillation","2025-04-21",{"date":118,"type":44},"2025-04-29",{"date":120,"type":44},"2024-08-16",{"date":122,"type":21},"2025-09",{"name":124,"class":51},"Nedim Tojaga",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":52},"100587000","responding-to-af-pill-in-pocket-anticoagulation-guided-by-automated-monitoring-and-alerts-100587000","NCT06922695","Responding to AF: Pill-in-Pocket Anticoagulation Guided by Automated Monitoring and Alerts","Pill-in-Pocket Oral Anticoagulation Responding to Atrial Fibrillation Episodes Guided by Continuous Rhythm Monitoring and Automated Smartphone Alerts","RESPOND-AF","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the trial.\n2. Understand the risk and willing to discontinue oral anticoagulation (OAC).\n3. Any gender aged 18 years or above.\n4. Non-valvular paroxysmal atrial or persistent atrial fibrillation (AF) with a current rhythm control strategy. Paroxysmal patients must have \\\u003C 3 documented or symptomatic episodes of \\>1 hour duration in the previous 3 months. Persistent patients must have been in continuous sinus rhythm for at least 4 weeks prior to enrolment.\n5. CHA2DS2-VASc score between 1 and 3 in men and between 2 and 4 in women.\n6. Able to take direct-acting oral anticoagulant (DOAC) in guideline recommended doses.\n7. Left atrial (LA) diameter on echocardiogram less than 5 cm (anteroposterior dimensions) or LA volume less than 48 ml\u002Fm2.\n\nExclusion Criteria:\n\n1. Any contraindication to OAC therapy with a DOAC in guideline recommended doses.\n2. Mechanical heart valve prosthesis or moderate-to-severe mitral valve stenosis.\n3. Permanent atrial fibrillation.\n4. Hypertrophic cardiomyopathy.\n5. Documented previous thromboembolic event (stroke, transient ischaemic attack or systemic embolism).\n6. Spontaneous echo contrast observed in any imaging modality.\n7. History of intracardiac thrombi.\n8. History of congenital heart disease.\n9. Severe chronic renal disease (eGFR \\\u003C15 ml\u002Fm) or on renal replacement therapy.\n10. Pregnant or planning pregnancy.\n11. Indication for OAC other than atrial fibrillation.\n12. Inability to comply with protocol.\n13. Smartphone with operating system (OS) not compatible with MyCareLink Heart app.\n14. Contraindication for implantable cardiac monitor.\n15. Visual or physical impairment that prevents ability to read and acknowledge smartphone\u002Fwatch notifications.",{"count":134,"type":21},50,[24],"Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 1-2 million people in the UK. AF is characterised by uncoordinated electrical activation and ineffective contraction of the upper cardiac chambers. AF can occur in temporary episodes, as in paroxysmal AF, or can be sustained continuously beyond 7 days' duration, as in persistent AF.\n\nThe most significant potential complication of AF is stroke caused by a blood clot (thromboembolic stroke). If untreated, the risk of stroke in AF can be increased as much as five-fold, depending on the presence of other risk factors.\n\nThe mechanism of thromboembolic stroke in AF patients is complicated and understanding of factors involved remains incomplete. AF has been shown to disrupt normal bodily mechanisms for controlling bleeding and clotting (haemostasis) and normal blood flow inside the cardiac chambers. In disrupting these mechanisms, AF can be said to create a 'prothrombotic' state or environment within the blood and heart (a tendency to form clots) which can lead to blood clot formation and subsequently to stroke.\n\nThere is research evidence that AF-related stroke risk is not fixed and changes over time. This dynamic risk may be related to the episodic nature of AF, with stroke risk changing during an episode of AF and for a period of weeks after the episode terminates.\n\nAnalytic studies have shown that the risk of stroke is highest in the days after an AF episode has occurred, peaking at 5 days and returning to baseline by 30 days. Other studies have shown that the duration of the AF episode can also influence the risk of stroke following each episode, with longer episodes being higher risk.\n\nThis dynamic risk likely relates to changes in the activation of the body's blood-clotting system and changes in blood flow within the heart.\n\nCurrent clinical guidelines recommend that patients with AF and risk factors for stroke are treated with daily, uninterrupted anticoagulation (blood-thinning medication) to reduce the risk of stroke. These guidelines do not take into account the temporal pattern of AF or the frequency or duration of AF episodes.\n\nAn emerging approach to anticoagulation in AF is pill-in-pocket oral anticoagulation (PIPOAC). In this approach, AF patients only take their anticoagulation in response to episodes of AF, and for a period of time after normal heart rhythm is restored. This approach may suit AF patients who have lower risk, lower frequency AF and who wish to reduce their exposure to anticoagulation medication. It may also suit AF patients who have higher bleeding risk related to anticoagulation.\n\nThe RESPOND-AF study proposes a novel approach to delivering PIPOAC. It is a pilot study of this novel approach recruiting 50 participants. This includes participants having continuous heart rhythm monitoring using the Medtronic LINQ II implantable cardiac monitor. The LINQ II continuously monitors for evidence of AF. If AF is detected a transmission is uploaded to the Medtronic Carelink cloud portal.\n\nTraditionally, healthcare professionals need to sign in to this portal to check for any transmissions. For the purposes of PIPOAC this traditional approach would be too slow and create a burdensome workload for clinicians. Due to the properties of blood clot formation in AF, it is important to initiate oral anticoagulation within 48 hours of AF episode onset to disrupt the clot-formation process.\n\nFor the purposes of this study, the investigators have developed a custom-designed software which continuously screens for transmissions of AF on the Carelink cloud portal. When an AF episode has been detected by the LINQ II monitor, the software will send an SMS smartphone alert to the patient informing them of the AF episode and instructing them to commence their oral anticoagulation as soon as possible. This approach, if shown to be safe and effective and acceptable to patients, could open the path to wider use of Pill-in-pocket oral anticoagulation.\n\nThis novel treatment can reduce the need for anticoagulation, meaning fewer bleeding complications. Pill-in-pocket oral anticoagulation empowers patients by offering a new treatment choice beyond current limited options.",[66,27],[139,140,141,142,143],"Atrial Fibrillation","Pill-in-pocket anticoagulation","Anticoagulation","As-required anticoagulation","Intermittent anticoagulation","2025-04-17",{"date":146,"type":44},"2025-04-23",{"date":148,"type":44},"2025-04-14",{"date":150,"type":21},"2027-04-15",{"name":152,"class":51},"Oxford University Hospitals NHS Trust"]